BeiGene Starts China Clinical Trial of Melanoma Drug

BeiGene, an innovative Beijing oncology pharma, received CFDA approval to conduct China Phase I clinical trials of BGB-283, a novel RAF dimer inhibitor. BeiGene will test the drug in solid tumors with B-RAF mutations or other aberrations in the RAS-MAPK (mitogen-activated protein kinase) pathway; one of the major targets will be melanoma. In 2003, BeiGene out-licensed ex-China rights for BGB-283 to Merck Serono in a $233 million deal. BeiGene began a trial of the drug candidate in Australia in December 2003 More details.... Share this with colleagues: // //